Eupraxia Pharmaceuticals
EPRX
11 hedge funds and large institutions have $7.09M invested in Eupraxia Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1,449% more capital inflows, than outflows
Capital inflows: $1.27M | Capital outflows: $81.8K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0.92% more ownership
Funds ownership: 5.13% → 6.05% (+0.92%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Scotia Capital
Toronto,
Ontario, Canada
|
+$556K |
| 2 |
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$362K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$206K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$80.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$41.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
180 Wealth Advisors
Federal Way,
Washington
|
-$33.3K |
| 2 |
Millennium Management
New York
|
-$31.3K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$15.5K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
-$1.66K |
EPRX Hedge Fund Activity: Q1 2025 in Review
11 of the 7,487 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q1 2025, worth a combined $7.09M — up 26% from $5.63M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EPRX positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Scotia Capital, adding an estimated $556K. The largest seller was 180 Wealth Advisors, exiting entirely with an estimated $33.3K sold.
- 11 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q1 2025, up from 9 in Q4 2024.
- Funds reported $7.09M of Eupraxia Pharmaceuticals stock for Q1 2025, up 26% quarter-over-quarter.
- 4 funds opened new Eupraxia Pharmaceuticals positions in Q1 2025 and 2 closed out, a net change of +2 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q1 2025 was Scotia Capital, an estimated $556K added.
- The largest Eupraxia Pharmaceuticals seller in Q1 2025 was 180 Wealth Advisors, an estimated $33.3K sold.
Based on aggregated 13F filings for Q1 2025.